Remove 2011 Remove Leads Remove Networking
article thumbnail

Understanding the evidence used in drug product withdrawals

European Pharmaceutical Review

Between 1999 and 2001, it supported 17 percent of withdrawals, between 2002 and 2011, it supported 26 percent of withdrawals and by 2012 to 2016, 80 percent of withdrawals were supported by observational studies (cohort, case-control, or other epidemiologic design). Meta-analyses contributed least frequently (31.4 2018; 8(1). EMA/95098/2010.

Medicine 116
article thumbnail

The EU HTA regulation: a new frontier for access to innovative technologies

European Pharmaceutical Review

1 The regulation is the culmination of a long debate between European Union (EU) Member States and health sector stakeholders, triggered by joint actions such as European Network for Health Technology Assessment (EUnetHTA) and formalised through the European Commission (EC)’s proposal in January 2018. effectiveness and therapeutic efficacy.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Strengthening and transforming the pharmaceutical supply chain

European Pharmaceutical Review

A recent report from the US Food and Drug Administration (FDA) shows that while the number of new drug shortages has fallen significantly from a high of 250 in 2011 to 49 in 2022, there was an increase in new drug shortages year-on-year. Going forward, it is imperative for companies to invest in constructing more resilient supply networks.

article thumbnail

How Royal Philips supports growing IP administration demands with integrated Clarivate services and technology [Customer Story]

Clarivate

Royal Philips is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. In 2011, following a review of available IP management software (IPMS), Philips adopted Unycom. Unycom offers comprehensive tools for managing the entire IP lifecycle.

article thumbnail

Industry Leader Julie Adrian Appointed by FINN Partners to Accelerate Growth of Agency’s UK Health Group

PM360

17, 2024 – FINN Partners, one of the world’s leading independent marketing and communications agencies, today announces the appointment of Julie Adrian as Managing Partner and UK Health Group Lead. In addition, FINN provides its clients with access to top-tier agencies worldwide through its membership in the global network PROI.

Leads 52
article thumbnail

Three Steps to Hitting Your MLR Targets in 2021 

Clarify Health

Prior to 2011 when the Affordable Care Act (ACA) was passed, many insurance companies were spending a large portion of premium dollars on administrative costs and profits. Health plans should prioritize high-value providers to include in their network based on case-mix adjusted clinical, quality and cost-efficiency scores.

article thumbnail

Paving the way for anti-Abeta active immunotherapy

European Pharmaceutical Review

Targeting toxic species of Abeta, such as multimers (with aducanumab and lecanemab) or pyroglutamate Abeta3-42 (with donanemab), induced significant removal of Abeta plaque load in the brains of Alzheimer’s patients, leading to the delay in cognitive decline. Treatment with the mAbs delayed cognitive decline by 2.6 months for lecanemab and 5.5